Show simple item record

dc.contributor.authorBernardo, BC
dc.contributor.authorGregorevic, P
dc.contributor.authorRitchie, RH
dc.contributor.authorMcMullen, JR
dc.date.accessioned2020-06-23T13:38:58Z
dc.date.available2020-06-23T13:38:58Z
dc.date.issued2018-09-21
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445215700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4d813f4571fa7d6246bdc0dfeca3a1c
dc.identifierARTN 1090
dc.identifier.citationBernardo, B. C., Gregorevic, P., Ritchie, R. H. & McMullen, J. R. (2018). Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges. FRONTIERS IN PHARMACOLOGY, 9 (SEP), https://doi.org/10.3389/fphar.2018.01090.
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/11343/240785
dc.description.abstractHeart failure (HF) is a debilitating and deadly chronic disease, with almost 50% of patients with HF dying within 5 years of diagnosis. With limited effective therapies to treat or cure HF, new therapies are greatly needed. microRNAs (miRNAs) are small non-coding RNA molecules that are powerful regulators of gene expression and play a key role in almost every biological process. Disruptions in miRNA gene expression has been functionally linked to numerous diseases, including cardiovascular disease. Molecular tools for manipulating miRNA activity have been developed, and there is evidence from preclinical studies demonstrating the potential of miRNAs to be therapeutic targets for cardiovascular disease. For clinical application, miRNA sponges and tough decoys have been developed for more stable suppression and targeted delivery of the miRNA of choice. The aim of this study was to generate miRNA sponges and tough decoys to target miR-34 in the mouse heart. We present data to show that using both approaches we were unable to get significant knockdown of miR-34 or regulate miR-34 target genes in the heart in vivo. We also review recent applications of this method in the heart and discuss further considerations for optimisation in construct design and testing, and the obstacles to be overcome before they enter the clinic.
dc.languageEnglish
dc.publisherFRONTIERS MEDIA SA
dc.titleGeneration of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges
dc.typeJournal Article
dc.identifier.doi10.3389/fphar.2018.01090
melbourne.affiliation.departmentPaediatrics (RCH)
melbourne.affiliation.departmentPhysiology
melbourne.affiliation.departmentPharmacology and Therapeutics
melbourne.source.titleFRONTIERS IN PHARMACOLOGY
melbourne.source.volume9
melbourne.source.issueSEP
dc.rights.licenseCC BY
melbourne.elementsid1350930
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160554
melbourne.contributor.authorBernardo, Bianca
melbourne.contributor.authorGregorevic, Paul
melbourne.contributor.authorRitchie, Rebecca
dc.identifier.eissn1663-9812
pubs.acceptance.date2018-09-07
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record